Literature DB >> 19787377

[Epidemiology and therapy of pain and depression during HIV and AIDS].

I W Husstedt1, D Reichelt, F Kästner, S Evers, K Hahn.   

Abstract

Pain is one of the most common reasons for admission to hospital for patients suffering from AIDS. Pain and other symptoms very often cover depressive episodes. Pain induced by AIDS therapy represents a progressive problem and induces the necessity to alter the highly active antiretroviral therapy (HAART). Of HIV-infected people 90% complain of headaches. Headache may result from opportunistic infections, from side-effects of HAART or from the HIV in the CNS itself but also the high burden of idiopathic headaches must be considered. Up to 20% of all neuropathies in HIV-infected people are caused by HAART. In most cases changing of HAART is necessary. Problems of interactions between HAART and the substances used for pain therapy via the cytochrome P450 system represents a special therapeutic problem during HAART in order to avoid development of resistance by the HIV.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19787377     DOI: 10.1007/s00482-009-0846-x

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  54 in total

1.  Human immunodeficiency virus and the peripheral nervous system workshop.

Authors:  F J Brinley; C A Pardo; A Verma
Journal:  Arch Neurol       Date:  2001-10

2.  Guillain-Barré syndrome associated with human immunodeficiency virus infection in Zimbabwe.

Authors:  C A Thornton; A S Latif; J C Emmanuel
Journal:  Neurology       Date:  1991-06       Impact factor: 9.910

Review 3.  Ganciclovir and foscarnet efficacy in AIDS-related CMV polyradiculopathy.

Authors:  H J Anders; N Weiss; J R Bogner; F D Goebel
Journal:  J Infect       Date:  1998-01       Impact factor: 6.072

4.  Peripheral neuropathy in human immunodeficiency virus-infected patients with the diffuse infiltrative lymphocytosis syndrome.

Authors:  A Moulignier; F J Authier; M Baudrimont; G Pialoux; L Belec; M Polivka; B Clair; F Gray; J Mikol; R K Gherardi
Journal:  Ann Neurol       Date:  1997-04       Impact factor: 10.422

5.  Ischaemic cerebrovascular events in HIV infection: a cohort study.

Authors:  Stefan Evers; Darius Nabavi; Alexandra Rahmann; Christoph Heese; Doris Reichelt; Ingo-W Husstedt
Journal:  Cerebrovasc Dis       Date:  2003       Impact factor: 2.762

6.  Markers of immune activation and viral load in HIV-associated sensory neuropathy.

Authors:  G Schifitto; M P McDermott; J C McArthur; K Marder; N Sacktor; D R McClernon; K Conant; B Cohen; L G Epstein; K Kieburtz
Journal:  Neurology       Date:  2005-03-08       Impact factor: 9.910

7.  Pain and other symptoms in ambulatory HIV patients in the age of highly active antiretroviral therapy.

Authors:  Gayle Newshan; JoAnne Bennett; Susan Holman
Journal:  J Assoc Nurses AIDS Care       Date:  2002 Jul-Aug       Impact factor: 1.354

8.  A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team.

Authors:  K Kieburtz; D Simpson; C Yiannoutsos; M B Max; C D Hall; R J Ellis; C M Marra; R McKendall; E Singer; G J Dal Pan; D B Clifford; T Tucker; B Cohen
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

9.  Complement dependent cytotoxicity of sensory ganglion neurons mediated by the gp120 glycoprotein of HIV-1.

Authors:  S Apostolski; T McAlarney; A P Hays; N Latov
Journal:  Immunol Invest       Date:  1994-01       Impact factor: 3.657

10.  [Differential diagnosis and therapy of headache in HIV infection].

Authors:  I W Wibbeke; S Evers; G Husstedt
Journal:  Schmerz       Date:  2000-08       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.